Label: information for the user
Erleada 240 mg film-coated tablets
apalutamida
Read this label carefully before starting to take this medicine, as it contains important information for you.
What is Erleada
Erleada is a cancer medication that contains the active ingredient apalutamida.
How is Erleada used
It is used to treat adult men with prostate cancer that:
How Erleada works
Erleada works by blocking the activity of hormones called androgens (such as testosterone). Androgens can cause cancer growth. By blocking the effect of androgens, apalutamida causes prostate cancer cells to stop growing and dividing.
Do not take Erleada
Do not take this medicine if any of the above applies to you. If you are unsure, consult your doctor or pharmacist before taking this medicine.
Warnings and precautions
Consult your doctor or pharmacist before starting to take this medicine if:
If any of the above applies to you (or you are unsure), consult your doctor or pharmacist before taking this medicine.
Falls and bone fractures
Falls have been observed in patients taking Erleada. Take special precautions to reduce the risk of falls. Bone fractures have been observed in patients taking this medicine.
Heart disease, stroke, or mini-stroke
Some people have experienced a blockage of the heart or brain arteries that can cause death during treatment with Erleada.
Your doctor will monitor you for signs and symptoms of heart or brain problems during treatment with this medicine.
Call your doctor or go to the nearest emergency center immediately if you have:
If you are taking any medicine, consult your doctor or pharmacist to see if they are associated with a higher risk of seizures, bleeding, or heart problems.
Severe skin reactions (SSRs)
Severe skin reactions, including drug reaction with eosinophilia and systemic symptoms or DRESS or Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/NET), have been reported with the use of Erleada. DRESS may appear as a generalised rash, high body temperature, and enlarged lymph nodes. SJS/NET may initially appear on the trunk as red target-shaped patches or circular patches with central blisters. In addition, they may produce mouth ulcers, throat ulcers, nasal ulcers, genital ulcers, and eye ulcers (red and swollen eyes). These severe skin reactions often precede generalised skin peeling and potentially fatal or fatal complications.
If you develop a severe rash or any of these symptoms, stop taking this medicine and contact your doctor or seek medical attention immediately.
If any of the above applies to you (or you are unsure), consult your doctor or pharmacist before taking this medicine. See the section "Serious side effects" in section 4 for more information.
Children and adolescents
This medicine should not be used in children or adolescents under 18 years of age.
If a child or young person takes this medicine by mistake:
Other medicines and Erleada
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medicine, as Erleada may affect the functioning of other medicines. Also, other medicines may affect the functioning of Erleada.
Specifically, inform your doctor if you are taking medicines for:
You should make a list of the names of the medicines you are taking and show it to your doctor or pharmacist when you start taking a new medicine. Inform your doctor that you are taking Erleada if your doctor wants to start any new treatment. It may be necessary to change the dose of Erleada or any of the other medicines you are taking.
Information on pregnancy and contraception for men and women
Information for women
Information for men: follow these guidelines during treatment and for 3 months after stopping
Use contraception during treatment and for 3 months after stopping. Consult your doctor if you have any questions about contraception.
This medicine may reduce male fertility.
Driving and operating machinery
It is unlikely that Erleada will affect your ability to drive or use any tool or machine.
The side effects of this medicine include seizures. If you have a higher risk of seizures (see Section 2, 'Warnings and precautions'), consult your doctor.
Erleada contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per dose of 240 mg (1 tablet); this is, essentially, "sodium-free".
Follow exactly the administration instructions of this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
Your doctor may prescribe other medications while you are taking Erleada.
How much to take
The recommended dose of this medication is 240 mg (one tablet) once a day.
How to take Erleada
If you cannot swallow the tablet
If you take more Erleada than you should
If you take more than you should, stop taking this medication and contact your doctor.
You may be at a higher risk of experiencing side effects.
If you forget to take Erleada
If you forget to take this medication, take the usual dose as soon as you remember the same day.
If you interrupt treatment with Erleada
Do not stop taking this medication without consulting your doctor first.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Severe side effects
Stop taking Erleada and seek medical attention immediately if you notice any of the following symptoms:
Inform your doctor immediately if you notice any of the following severe side effects, your doctor may suspend treatment:
Very common: may affect more than 1 in 10 people
Common:may affect up to 1 in 10 people
Uncommon: may affect up to 1 in 100 people
Inform your doctor immediately if you notice any of the severe side effects mentioned above.
Side effects include
Inform your doctor immediately if you notice any of the following side effects:
Very common(may affect more than 1 in 10 people):
Common:(may affect up to 1 in 10 people):
Uncommon(may affect up to 1 in 100 people):
Not known(the frequency cannot be estimated from available data):
Inform your doctor immediately if you notice any of the side effects mentioned above.
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging (blister, inner case, outer case, bottle, and box) after CAD. The expiration date is the last day of the month indicated.
Store in the original packaging to protect it from moisture. This medication does not require any special storage temperature.
Medicines should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the packaging and medications that you no longer need. This will help protect the environment.
Composition of Erleada
Appearance of the product and contents of the pack
Erleada film-coated tablets are blue-gray to gray film-coated tablets, oval shape (21 mm long by 10 mm wide), with "E240" engraved on one face.
The tablets may be presented in a bottle or in a carton. Only some pack sizes may be marketed.
Bottle
The tablets are presented in a child-resistant plastic bottle with a safety closure. Each bottle contains 30 tablets and a total of 2 g of desiccant. Each carton contains one bottle. Keep in the original packaging. Do not ingest or dispose of the desiccant.
28-day pack
Each 28-day pack contains 28 film-coated tablets in 2 cartons of 14 film-coated tablets each.
30-day pack
Each 30-day pack contains 30 film-coated tablets in 3 cartons of 10 film-coated tablets each.
Marketing authorization holder
Janssen-Cilag International NV
Turnhoutseweg 30
B-2340 Beerse
Belgium
Responsible for manufacturing
Janssen Cilag SpA
Via C. Janssen
Borgo San Michele
04100 Latina, Italy
For further information about this medicinal product, please contact the local representative of the marketing authorization holder:
België/Belgique/Belgien Janssen-Cilag NV Tel/Tél: +32 14 64 94 11 | Lietuva UAB "JOHNSON & JOHNSON" Tel: +370 5 278 68 88 |
Luxembourg/Luxemburg Janssen-Cilag NV Tél/Tel: +32 14 64 94 11 | |
Ceská republika Janssen-Cilag s.r.o. Tel.: +420 227 012 227 | Magyarország Janssen-Cilag Kft. Tel.: +36 1 884 2858 |
Danmark Janssen-Cilag A/S Tlf: +45 4594 8282 | Malta AM MANGION LTD. Tel: +356 2397 6000 |
Deutschland Janssen-Cilag GmbH Tel: +49 2137 955 955 | Nederland Janssen-Cilag B.V. Tel: +31 76 711 1111 |
Eesti UAB "JOHNSON & JOHNSON" Eesti filiaal Tel: +372 617 7410 | Norge Janssen-Cilag AS Tlf: +47 24 12 65 00 |
Österreich Janssen-Cilag Pharma GmbH Tel: +43 1 610 300 | |
España Janssen-Cilag, S.A. Tel: +34 91 722 81 00 | Polska Janssen-Cilag Polska Sp. z o.o. Tel.:+48 22 237 60 00 |
France Janssen-Cilag Tél: 0 800 25 50 75 / +33 1 55 00 40 03 | Portugal Janssen-Cilag Farmacêutica, Lda. Tel: +351 214 368 600 |
Hrvatska Johnson & Johnson S.E. d.o.o. Tel: +385 1 6610 700 | România Johnson & Johnson România SRL Tel: +40 21 207 1800 |
Ireland Janssen Sciences Ireland UC Tel: 1 800 709 122 | Slovenija Johnson & Johnson d.o.o. Tel: +386 1 401 18 00 |
Ísland Janssen-Cilag AB c/o Vistor hf. Sími: +354 535 7000 | Slovenská republika Johnson & Johnson, s.r.o. Tel: +421 232 408 400 |
Italia Janssen-Cilag SpA Tel: 800.688.777 / +39 02 2510 1 | Suomi/Finland Janssen-Cilag Oy Puh/Tel: +358 207 531 300 |
Sverige Janssen-Cilag AB Tfn: +46 8 626 50 00 | |
Latvija UAB "JOHNSON & JOHNSON" filiale Latvija Tel: +371 678 93561 | United Kingdom (Northern Ireland) Janssen Sciences Ireland UC Tel: +44 1 494 567 444 |
Last update of the summary of product characteristics:
Other sources of information
The detailed information on this medicinal product is available on the website of the European Medicines Agency: http://www.ema.europa.eu/, and on the website of the Spanish Agency of Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es/).
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.